The New-Issue Window Is Wide Open — But the Bill Comes Due

The U.S. IPO market is having its busiest first half in nearly a decade, and the deals landing in early July suggest the window is not narrowing yet. Renaissance Capital data shows that 79 U.S. IPOs have already raised $112.5 billion so far in 2026, up 625% year over year{{cite:chatcmpltool}}. Roughly 50 U.S. listings have reached the market, and new issues are up an average of 22% from their offer prices year to date{{cite:chatcmpltool}}. The question is no longer whether the window is open. It is how much equity supply the market can absorb before that supply starts pulling capital away from the existing holdings that drove the rally.

Bending Spoons: the deal that defied the SaaS slump

The marquee transaction of the week was Bending Spoons, the Milan-based software roll-up whose portfolio includes AOL, Vimeo, WeTransfer, Evernote, Eventbrite, and Brightcove. The company priced 57.97 million shares at $29.00 — a dollar above its $26–$28 marketed range — raising approximately $1.68 billion in total, with 34.4 million primary shares and 23.57 million secondary shares from existing holders including Baillie Gifford{{cite:chatcmpltool}}. On its Nasdaq debut under the ticker BSP, shares surged roughly 40%{{cite:chatcmpltool}}.

What makes the debut notable is the backdrop. Traditional SaaS stocks have been under pressure in 2026 amid investor concern that AI-built software could displace existing platforms. Bending Spoons cleared that hurdle by framing itself not as a SaaS innovator but as a serial acquirer that applies operational transformation to established digital businesses — a private-equity-style model applied to consumer software, serving over 500 million monthly active users{{cite:chatcmpltool}}. The aftermarket reception suggests investors are willing to reward that distinction, though the 40% first-day pop also means the company left money on the table at pricing — the classic IPO underpricing trade-off that benefits flip-and-flip institutional buyers more than the issuer.

Lime: micromobility finally goes public

Lime, officially Neutron Holdings, priced its IPO at $25.00 — the midpoint of its $24–$26 range — selling 6.96 million shares to raise $174 million, with a market capitalization of approximately $1.6 billion at pricing{{cite:chatcmpltool}}. Goldman Sachs, J.P. Morgan, and Jefferies led the syndicate. Shares opened at $27 on Nasdaq, an 8% first-day gain{{cite:chatcmpltool}}.

Uber, which holds a 24.4% pre-IPO stake in Lime (diluting to 21.9% post-offering), indicated interest in buying up to $20 million of stock in the deal{{cite:chatcmpltool}}. Lime intends to use the proceeds to repay all $115 million of its 10% senior secured term loan maturing in September 2026 and to convert remaining debt into equity — effectively making the company debt-free after the IPO, with a new $200 million revolving credit facility available but undrawn{{cite:chatcmpltool}}.

The financial profile is the part worth examining honestly. Lime reported a net loss of $64.6 million on revenue of $927.9 million for the trailing twelve months ended March 2026{{cite:chatcmpltool}}. That is a company with meaningful top-line scale and a path to profitability, but it is not yet profitable. Investors who bought the debut are paying for that path, not for current earnings — which makes Lime a useful test case for whether the 2026 IPO market is rewarding quality or simply rewarding supply scarcity in a risk-on environment.

The secondary market is just as active

If IPOs are the headline, secondary offerings are the undercurrent — and the undercurrent is running strong.

Abivax stands out. The Paris-based biotechnology company, dual-listed on Euronext Paris and Nasdaq, priced its U.S. offering of 7.36 million ADSs (including full over-allotment) at $125.00 per ADS, generating approximately $920 million in gross proceeds — a deal that was upsized twice from an initial $600 million target and described as highly oversubscribed{{cite:chatcmpltool}}. The proceeds are earmarked for potential U.S. commercialization of obefazimod, its Phase 3 drug candidate for ulcerative colitis and Crohn’s disease, plus clinical R&D{{cite:chatcmpltool}}. The fact that a clinical-stage biotech with no approved drug can raise nearly $1 billion in a public follow-on tells you something about the depth of demand in the current market — and about how selective that demand remains. It is concentrated in sectors where the narrative is clear: immunology, AI infrastructure, defense.

Sable Offshore’s transaction illustrates the other end of the spectrum — a capital-intensive energy company raising both equity and convertible debt simultaneously, pricing 32.47 million shares at $3.08 alongside $300 million in 6.5% convertible senior notes due 2031{{cite:chatcmpltool}}. That concurrent-structure deal is a sign that underwriters are confident enough in placement capacity to run multi-leg transactions, something that was rare during the 2023–2024 issuance drought.

Buybacks: the offsetting current

On the other side of the capital-flow ledger, corporate buybacks are running at historically elevated levels, creating a partial offset to the equity supply from new issuance.

NVIDIA announced an $80 billion additional share repurchase authorization alongside a dividend increase from $0.01 to $0.25 per share — a 2,400% hike — when it reported Q1 FY2027 results in May{{cite:chatcmpltool}}. Record quarterly revenue of $81.6 billion, up 85% year over year, provided the cash-flow base for that authorization{{cite:chatcmpltool}}.

Other notable recent buyback announcements include Accenture increasing its fiscal year 2026 repurchase program by $2 billion to $7.5 billion total (a 62% year-over-year increase){{cite:chatcmpltool}}, Visteon authorizing an $800 million repurchase program expiring December 31{{cite:chatcmpltool}}, and Intesa Sanpaolo launching a €2.3 billion buyback approved by the ECB{{cite:chatcmpltool}}. Playboy also moved to repurchase 16.6 million shares from Fortress at a 28% discount to market value, representing nearly 15% of outstanding shares{{cite:chatcmpltool}}.

The interplay matters. New issuance adds shares to the float; buybacks remove them. When both are running hard, the net effect on aggregate market liquidity depends on the balance — and right now, the buyback side is being dominated by a small number of mega-cap companies led by NVIDIA, while the issuance side is broadening across sectors and market caps. That is a structural shift worth watching: the supply-demand equilibrium for equity is being tested from both directions simultaneously.

Market structure: calm on the surface, nervous underneath

The VIX closed at 15.81 on July 2, down 2.11%{{cite:chatcmpltool}}, and the S&P 500 posted its best quarter since 2020{{cite:chatcmpltool}}. By those surface measures, the market is calm. But beneath the surface, the options market is showing signs of hedging activity: SKEW climbed to its highest level in recent sessions even as the VIX fell{{cite:chatcmpltool}}. SKEW measures the price of out-of-the-money put options relative to at-the-money options — a proxy for tail-risk hedging. When SKEW rises while VIX falls, it typically means large investors are paying up for downside protection even as realized volatility stays low.

That divergence is relevant to the issuance picture. A low VIX and a strong quarterly performance are the conditions under which IPO windows open widest — underwriters price deals when volatility is compressed and risk appetite is elevated. But elevated SKEW suggests that at least some institutional money is positioning for a dislocation that the headline indices are not yet reflecting. If those hunches are right, the current window could narrow quickly; if they are wrong, the hedges will expire worthless and the issuers who rushed to market will look prescient for taking advantage of the calm.

The June payrolls report added another wrinkle. Jobs data missed expectations badly, pushing the market’s priced Fed hike out to December{{cite:chatcmpltool}}. A delayed hike trajectory is nominally supportive of risk assets and IPO pricing, but the miss itself signals potential economic deceleration — which would eventually compress the earnings base that supports the multiples being paid in the new-issue market.

The global picture is not just a U.S. story

Issuance strength is not confined to the United States. China Resources New Energy, the renewable energy subsidiary of China Resources Power, completed what was described as Asia’s biggest IPO of 2026 on the Shenzhen Stock Exchange, raising approximately $3.6 billion. Shares rose 136.9% on the first day of trading, from an IPO price of CNY 10.11 to a close of CNY 23.95, reaching a market value of approximately $46 billion{{cite:chatcmpltool}}. Six companies are also scheduled to list on the Indonesia Stock Exchange in July, with healthcare firms accounting for half the pipeline{{cite:chatcmpltool}}.

In Hong Kong, TrueHealth Medical debuted on HKEX with a 216.96% first-day rally as the first Hong Kong-listed percutaneous surgical robotics company{{cite:chatcmpltool}}. These performances indicate that investor appetite for new listings is a global phenomenon in 2026, not a U.S.-specific rerating — though the strongest demand remains concentrated in specific sectors: renewable energy, healthcare, AI infrastructure, and defense.

What would have to be true for each side

The bullish case for continued issuance is straightforward: the pipeline is deep, investor demand is broad, and the macro backdrop — with a delayed Fed hike and a strong first half — supports risk appetite. Renaissance Capital’s count of 203 announced IPOs year to date places 2026 at its third-highest clip in the last decade{{cite:chatcmpltool}}. Cumberland Farms and Jersey Mike’s have both filed, and confidential submissions from OpenAI and Anthropic suggest the pipeline extends well into the back half of the year{{cite:chatcmpltool}}.

The bearish case rests on absorption capacity. If the full-year pipeline approaches the $200 billion range that some analysts have projected, the dilutive effect on existing holdings could be material — one estimate suggested that level of issuance could pull roughly $1 trillion in market value from incumbent stocks as investors rotate capital toward new deals{{cite:chatcmpltool}}. That is not a crash thesis; it is a rotation thesis. But rotation from the megacaps that drove the index higher into newly public companies of unproven profitability would be a structural drag on the same indices that made the window look safe enough to open in the first place.

What to watch next

• Post-holiday IPO calendar: The week after July 4 is tentatively quiet, but one mega-name is reportedly scheduled to list. Watch whether the calendar fills or thins as the summer progresses{{cite:chatcmpltool}}.
• Bending Spoons and Lime aftermarket follow-through: First-day pops are signaling, not proof. The 30-day mark will show whether institutional buyers are holding or distributing.
• Abivax closing and ADS trading: The offering is expected to close July 6. Watch the ADS discount to Euronext Paris ordinary shares for a read on cross-listing arbitrage pressure{{cite:chatcmpltool}}.
• NVIDIA buyback execution pace: The $80 billion authorization has no fixed timeline. Quarterly 10-Q disclosures will show whether repurchases are accelerating or being paced — and whether the offset to new issuance is growing or shrinking.
• VIX vs. SKEW divergence: If SKEW continues rising while VIX stays suppressed, the tail-risk hedging signal warrants attention. A sudden VIX catch-up to SKEW would be the kind of quiet indicator that precedes a window narrowing.
• Fed trajectory after the jobs miss: The market has pushed the next priced hike to December. If subsequent data confirms deceleration, the risk-asset support narrative weakens — and so does the pricing power that makes IPO windows stay open.
• Lock-up expiries: Three lock-up periods are expiring in the week ahead{{cite:chatcmpltool}}. Lock-up releases add secondary supply and are a leading indicator of whether early investors are taking profits or holding — a sentiment read for the next wave of issuers watching from the sidelines.

The base-rate reading is that IPO windows in periods of strong first-half performance and compressed volatility tend to stay open for six to twelve months before the supply-demand balance shifts. The current window opened in earnest in early 2026 and is now roughly at peak width. That does not mean it closes tomorrow. It means the marginal deal — the one that prices at the wide end of the range with a 40% pop — is increasingly the exception rather than the rule, and the deals that follow will be judged more on fundamentals and less on scarcity.